Clinical trials: Cardiomyopathy, Hypertrophic
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori
Left Ventricular Non-compaction Cardiomyopathy, Left Ventricular Failure
Value of Cardiac Magnetic Resonance (CMR) Derived Parameters for Diagnosing Left Ventricular Non-compaction Cardiomyopathy
Left ventricular non-compaction (LVNC) is a rare cardiomyopathy characterized by numerous excessively prominent left ventricular (LV) trabeculation and deep intertrabecular recesses communicating with the ventricular cavity and…
- Conditions
- Left Ventricular Non-compaction Cardiomyopathy, Left Ventricular Failure, Left Ventricular Hypertrophy
- Trial name
- NCT01481298
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Leipzig
Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
This study will examine the effectiveness of the drug cyclosporine in treating hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens.
- Trial name
- NCT00001965
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Danon Disease
Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B
This is a non-randomized open-label Phase 1 study to evaluate the safety and toxicity of gene therapy using a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2…
- Trial name
- NCT03882437
- Testing
- RP-A501
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Hypertrophic Cardiomyopathy
Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
The purpose of this study is to determine if a drug called atorvastatin will reduce the size and stiffness of the muscle in the left ventricle of the heart.
- Trial name
- NCT00317967
- Testing
- Atorvastatin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Calgary
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Real-World Effectiveness of Mavacamten in Canada
The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM)…
- Trial name
- MAVEN (NCT06338202)
- Testing
- Mavacamten
- Where
- Canada
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and…
- Trial name
- EXCITE-HCM (NCT05818605)
- Testing
- Moderate Intensity Exercise Program
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Hypertrophic Obstructive Cardiomyopathy, Mitral Regurgitation
Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
Septal myectomy is performed in selected cases to treat patients with hypertrophic obstructive cardiomyopathy (HOCM). The mechanism that causes obstruction involves both the outflow tract itself and the mitral apparatus, with the…
- Trial name
- NCT05850026
- Testing
- Septal myectomy and mitral valve repair with edge-to-edge technique
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Michele De Bonis